Cartesian Therapeutics, Inc. (RNAC)
NASDAQ: RNAC · Real-Time Price · USD
10.04
-0.19 (-1.86%)
At close: Aug 21, 2026, 4:00 PM EDT
10.20
+0.16 (1.59%)
After-hours: Aug 21, 2026, 7:37 PM EDT
Cartesian Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, Cartesian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $34.57. The average 1-year stock price forecast is 244.32% higher than the current stock price, while the lowest is $16 (+59.36%) and the highest is $44 (+338.25%).
Price Target: $34.57 (+244.32%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Cartesian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $38 | Buy | Maintains | $38 | +278.49% | Aug 18, 2026 |
| Mizuho Securities | Mizuho Securities | Buy Reiterates $40 | Buy | Reiterates | $40 | +298.41% | Aug 12, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $16 | Buy | Reiterates | $16 | +59.36% | Aug 7, 2026 |
| BTIG | BTIG | Buy Maintains $44 | Buy | Maintains | $44 | +338.25% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $25 | Buy | Reiterates | $25 | +149.00% | Aug 7, 2026 |
Financial Forecast
Revenue This Year
366.80K
from 2.80M
Decreased by -86.89%
Revenue Next Year
333.33K
from 366.80K
Decreased by -9.12%
EPS This Year
-2.78
from -4.99
EPS Next Year
-3.81
from -2.78
EPS and Forward PE are based on non-GAAP adjusted numbers.